TY - JOUR A2 - 马吉奥，奥雷利奥AU - 迩，萨利马AU - Noushad，Mariyam AU - Ashiq，谢花PY - 2019 DA - 2019年11月12日TI - REGAIN研究：回顾性研究，以评估的实效性，耐受性和安全性铁Carboxymaltose缺铁性贫血的管理孕妇SP - 4640635 VL - 2019 AB - 怀孕期间缺铁性贫血（IDA）的产生是因为预先存在的不足商店或复杂的生理变化，并可能导致严重的产妇和胎儿的并发症。口服铁，无论是作为硫酸或富马酸铁，具有或不具有叶酸，为IDA在妊娠的最常用的治疗。Intravenous (IV) iron has a role in the treatment of IDA in pregnancy, particularly in women who present late, display severe anemia (Hb ≤ 9 g/dL), or risk factors, and are intolerant/noncompliant of oral iron. Previously, administration of IV iron was minimal, owing to potentially serious anaphylactic reactions. Recently, new IV iron products have been developed, offering better compliance, tolerability, efficacy, and a good safety profile. Our study aimed to assess the effectiveness, safety, and tolerability of IV ferric carboxymaltose (FCM) in the treatment of IDA in pregnant women in the UAE. Data from 1001 pregnant women who received at least one administration of FCM (500, 1000, or 1500 mg) during their second or third trimester of pregnancy (2 years backward from study initiation) were collected retrospectively from electronic medical records at Corniche Hospital, Abu Dhabi, UAE. Results showed that 41.4% of the women were able to achieve an increase of ≥2 g/dL in blood hemoglobin overall. A change of ≥2 g/dL was achieved by 27.5% of women administered a dose of 500 mg, 39.2% of women administered a dose of 1000 mg, and 63.9% of women administered a dose of 1500 mg of IV FCM. This indicates a directly proportional relationship between increasing IV FCM dose and the increase of ≥2 g/dL in blood hemoglobin. A total of 7 (0.7%) women reported mild, nonserious adverse events during the study. Within the limits of this retrospective study, IV FCM therapy was safe and effective in increasing the mean hemoglobin of pregnant women with IDA. SN - 2090-1267 UR - https://doi.org/10.1155/2019/4640635 DO - 10.1155/2019/4640635 JF - Anemia PB - Hindawi KW - ER -